Ipamorelin, sometimes also spelled „ipamorelin,” is a lab-designed peptide with the chemical structure Aib-His-D-2-Nal-D-Phe-Lys-NH2. This means it is constructed from a specific sequence of five amino acid building blocks, including several unusual, non-standard components not found in typical dietary proteins [1]. It was developed by researchers working on creating a growth hormone-releasing compound. It emerged from a broader chemical program investigating a related family of peptides known as growth hormone-releasing peptides (GHRPs). Ipamorelin was specifically identified as a promising candidate after researchers removed a specific dipeptide segment from an earlier compound called GHRP-1 and refined the remaining structure [1].
In terms of basic classification, ipamorelin belongs to a category of compounds called growth hormone secretagogues. This means that it works by stimulating the body's own pituitary gland to release growth hormone, rather than being a growth hormone itself—a distinction discussed in more detail below.
What does Ipamorelin do?
Essentially, ipamorelin stimulates the release of growth hormone from the pituitary gland. Foundational studies establishing this were conducted in both laboratory conditions (in vitro) and on animals (in vivo) before any human data existed. In early tests using isolated rat pituitary cells, ipamorelin released growth hormone with a potency and efficacy comparable to a known compound called GHRP-6 [1]. When tested in live animals, first on anesthetized rats and then on conscious pigs, ipamorelin again induced significant, dose-dependent increases in growth hormone release. The effects were generally similar in magnitude to GHRP-6 [1].
A particularly significant finding from the same foundational research was that ipamorelin appeared to be remarkably selective in what it affected. When researchers measured other pituitary-related hormones in pigs, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, and thyroid-stimulating hormone (TSH), none of them were significantly altered by ipamorelin treatment [1].
Perhaps most notably, related compounds such as GHRP-6 and GHRP-2 also increased ACTH and cortisol, hormones associated with the body's stress response. Ipamorelin, however, did not induce a significant increase in either—even at doses over 200 times the amount needed to elicit its growth hormone-releasing effect [1].
This combination of properties—effectively raising growth hormone while largely leaving several other hormonal systems untouched—prompted the original researchers to describe ipamorelin as the first GHRP-type compound with a level of selectivity comparable to growth hormone-releasing hormone (GHRH) itself [1].
Ipamorelin is used for
Based strictly on published, peer-reviewed studies available to date, the most well-documented area of clinical research on ipamorelin in humans has actually concerned a context quite different from what most people searching for it expect: gastrointestinal-intestinal recovery following surgery. A randomized, placebo-controlled, phase 2, multicenter clinical trial specifically tested ipamorelin, administered as an intravenous infusion twice daily, in adult patients recovering from bowel resection surgery. The researchers assessed whether it could accelerate the return to normal digestive function, a common postoperative complication known as paralytic ileus [2].
This connection exists because the ghrelin receptor, which ipamorelin activates, also plays a documented role in gastrointestinal motility, not just in growth hormone release. This gave researchers a concrete clinical rationale to test it in the context of surgical recovery.
Beyond this postoperative application, ipamorelin has also been extensively studied in general growth hormone axis research. This includes studying its effects on growth hormone and IGF-1 levels, bone formation, body composition in animal models, and its pharmacokinetic behavior in human volunteers [1], [3].
It's important to be direct here. Despite this scope of research interest, ipamorelin has not received approval from the FDA or any comparable regulator for any of these uses, including for paralytic ileus, for which it was specifically tested. It remains classified as a research compound, not an approved drug. Uses discussed in fitness, anti-aging, or bodybuilding contexts go far beyond this foundational, more narrowly researched clinical study base.
Is Ipamorelin a Growth Hormone-Releasing Peptide (GHRP)?
Yes, ipamorelin is classified as a Growth Hormone Releasing Peptide (GHRP). It is a separate category from Growth Hormone Releasing Hormone (GHRH) analogs like CJC-1295. Understanding this distinction is key to understanding how ipamorelin actually works in the body.
Is Ipamorelin a GHRP or GHRH?
Ipamorelin belongs to the GHRP family, not GHRH. This classification stems directly from its receptor target, not simply nomenclature. In foundational pharmacological studies on ipamorelin, researchers utilized specific blocking agents for both GHRP-type and GHRH-type receptors to ascertain which pathway ipamorelin actually acted through. The findings clearly demonstrated that ipamorelin, much like the already known compound GHRP-6, stimulated growth hormone release via the „GHRP-like receptor,” not through the separate GHRH receptor pathway [1]. This GHRP-like receptor is more formally known today as the ghrelin receptor, or GHS-R1a (Growth Hormone Secretagogue Receptor type 1a). This is the same receptor that the naturally occurring hormone ghrelin activates, thus ipamorelin is often and accurately described as a ghrelin mimetic or ghrelin receptor agonist [4].
Within the broader category of GHRPs, original research specifically highlighted ipamorelin as being unusually selective compared to earlier compounds such as GHRP-1, GHRP-2, and GHRP-6. This is based on its lack of a significant effect on cortisol, ACTH, and several other pituitary hormones described above [1]. It is therefore often referred to in the scientific literature as the „first selective growth hormone secretagogue.”.
How Ipamorelin Works — Mechanism of Action
The mechanism of ipamorelin focuses on binding and activating the ghrelin receptor (GHS-R1a). This receptor is found primarily on growth hormone-producing cells, called somatotrophs, in the anterior pituitary gland, as well as in the hypothalamus region of the brain that helps regulate the broader growth hormone system [4]. A detailed scientific review of how growth hormone secretagogues integrate with the body’s natural ghrelin system revealed something important. This receptor system does not simply bypass the body’s normal hormonal checks and balances. Instead, it seems to work partly by helping to overcome some of the inhibitory „brakes” the body normally applies to growth hormone release. This includes partially overcoming the inhibitory effects of both blood glucose and somatostatin, the primary natural inhibitor of growth hormone secretion in the body [4].
The same review described the ghrelin receptor system as functioning as an amplifier for a separate GHRH signaling pathway. It acts somewhat in parallel with it, rather than as a complete substitute. This helps explain why GHRH analogs, such as CJC-1295, and ghrelin receptor agonists, such as ipamorelin, are often discussed together as acting through complementary, rather than redundant, mechanisms [4].
It is worth being precise about what „desensitization” or „inhibition” of somatostatin means in this context. Studies indicate that the ipamorelin pathway may partially bypass or reduce the inhibitory effect of somatostatin, rather than completely eliminating somatostatin's regulatory role. This implies that the body's natural feedback system remains at least partially intact, rather than being entirely circumvented. This is a crucial distinction from directly injecting growth hormone itself, as direct GH administration bypasses this same natural regulatory checkpoint altogether.
Is Ipamorelin a steroid, a growth hormone, or a peptide?
To clarify a common point of confusion upfront: ipamorelin is a peptide, not a steroid, and it's not Human Growth Hormone (HGH) itself, though it is closely related to the growth hormone system as a whole. Structurally, it's a chain of five amino acids [1]. This places it in a completely different chemical category than anabolic-and.
It is not growth hormone itself. It is rather classified specifically as a growth hormone secretagogue — a compound that stimulates the body to release its own growth hormone from the pituitary gland, as opposed to introducing external, synthetic growth hormone directly into the bloodstream [1], [4].
Ipamorelin is also not a SARM (Selective Androgen Receptor Modulator), which is a separate class of compounds that act directly on androgen receptors in muscle and bone tissue. Ipamorelin's target receptor, the ghrelin receptor, is a completely different biological system than the androgen receptor pathway that SARMs engage [4].
Similarly, ipamorelin is not a GLP-1 receptor agonist, a class of drugs that includes medications like semaglutide, used for diabetes and weight management. GLP-1 drugs work via the incretin hormone system involved in regulating blood sugar and appetite—a pathway distinct from the ghrelin/growth hormone axis that ipamorelin engages with, even though both ghrelin and GLP-1 systems have some input on appetite regulation more broadly.
Limitations of current evidence
The basic pharmacology of ipamorelin, including its ability to selectively elevate growth hormone without significantly impacting cortisol, ACTH, and several other pituitary hormones, is well-documented by peer-reviewed animal studies and early human trials [1]. Its most significant human clinical trial evidence base pertains specifically to post-operative gastrointestinal recovery [2]—a narrower and different application than the general wellness or performance-oriented goals often associated with the compound in informal contexts.
Its classification as a GHRP acting via the ghrelin receptor (GHS-R1a) is also well-established in the basic pharmacology literature [1] and supported by broader mechanistic reviews of the ghrelin signaling system [4]. The precise extent to which ipamorelin's pathway remains subject to the body's natural somatostatin-based feedback regulation, versus a more complete bypass of this system, is described in mechanistic and review literature. However, it has not been isolated and quantified specifically for ipamorelin in a dedicated human study measuring precisely this question. Broader claims about what ipamorelin „does” for muscle, fat loss, sleep, or anti-aging purposes extend beyond this foundational base of clinical and mechanistic evidence and should be regarded with appropriate caution.
Disclaimer
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or any equivalent regulatory body for any human use. This article is provided for general educational and informational purposes only, reflects the state of published scientific literature at the time of writing, and does not constitute medical advice. It is not manufactured or sold under the quality and safety oversight applicable to approved pharmaceuticals. The research summarized in this article comes from early-stage pharmacology, animal studies, a small number of human clinical trials, and mechanistic reviews, and does not establish that ipamorelin is safe or effective for general human use, including for fitness, anti-aging, or bodybuilding purposes. Nothing in this article should be interpreted as a recommendation to use, source, or administer ipamorelin. It does not identify, recommend, or endorse any specific supplier, brand, or product. Any individual considering the use of ipamorelin or any other peptide should consult with a qualified, licensed healthcare professional before making any decisions.
References
[1] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[3] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[4] Veldhuis, J. D., & Bowers, C. Y. (2010). Integrating GHS into the ghrelin system. International Journal of Peptides, 2010, Article 879503. https://doi.org/10.1155/2010/879503